Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrustTSC: Adjunctive Ganaxolone for TSC-related Epilepsy
2021-003441-38Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Mar 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tuberous sclerosis complex (TSC) and epilepsy comparing Ganaxolone + background antiseizure medications with Placebo + background antiseizure medications (2 arms). Started Mar 2022; status: completed.
02
Drugs
ganaxolone
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on 2021-003441-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003441-38.